SCHEMBL23779067

SCHEMBL23779067

COC1(CNc2cc3n(n2)CCN(C(=O)c2cc4ccccc4[nH]2)C3)CCOC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.42
▸ HRH4 Q9H3N8 4/20 0.42
▸ AKR1C3 P42330 1/20 0.40
▸ DRD3 P35462 8/20 0.40
▸ ADRB1 P08588 1/20 0.40
▸ HTR1A P08908 1/20 0.40
▸ ADRA2C P18825 1/20 0.40
▸ HTR2B P41595 1/20 0.40
▸ TMEM97 Q5BJF2 1/20 0.40
▸ SIGMAR1 Q99720 1/20 0.40
▸ DRD2 P14416 7/20 0.39
▸ NAMPT P43490 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23779063 0.90 HDAC6 (0.45) POLBSMN1; SMN2HDAC6HRH4AKR1C3
SCHEMBL23779072 0.88 POLB (0.46) POLBSMN1; SMN2HDAC6HRH4AKR1C3
SCHEMBL23779138 0.83 HDAC6 (0.45) POLBSMN1; SMN2HDAC6HRH4AKR1C3
SCHEMBL24319981 0.83 HDAC6 (0.43) HDAC6HRH4AKR1C3DRD3ADRB1
SCHEMBL23779114 0.81 HDAC6 (0.48) POLBSMN1; SMN2HDAC6HRH4AKR1C3
SCHEMBL23779139 0.80 HDAC6 (0.47) POLBSMN1; SMN2HDAC6HRH4AKR1C3
SCHEMBL22633538 0.79 POLB (0.42) POLBSMN1; SMN2HDAC6HRH4AKR1C3
SCHEMBL23779123 0.78 POLB (0.51) POLBSMN1; SMN2HDAC6HRH4AKR1C3
SCHEMBL24319834 0.78 HDAC6 (0.47) POLBSMN1; SMN2HDAC6HRH4AKR1C3
SCHEMBL23779107 0.77 HRH4 (0.53) POLBSMN1; SMN2HDAC6HRH4AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220081444-A1 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2022-03-17 — — US disclosed
US-20220081444-A1 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2022-03-17 — — US disclosed
EP-3873910-A1 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AiCuris GmbH & Co. KG (DE) 2021-09-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220081444-A1 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) HCCS, CDK2, BRD4 POLB 536/4885SMN1; SMN2 4877/4885HDAC6 897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback